3 assets in Oligoastrocytoma

Therapeutic assets addressing Oligoastrocytoma, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Cyclophosphamide Oligoastrocytoma	Dana-Farber Cancer Institute	P1	CC (43)
Nivolumab Oligoastrocytoma	University of Florida	P1	CC (43)
Rqnestin Oligoastrocytoma	Dana-Farber Cancer Institute	P1	CC (43)